Key clinical point: Once-daily oral atogepant was overall safe and effective for the prevention of episodic migraine in adults.

Major finding: The reduction in the mean number of migraine days across the 12-week treatment period was significantly greater with 10 mg atogepant (mean difference [MD] −1.16; P < .001), 30 mg (MD −1.15; P < .001), or 60 mg (MD −1.20; P  =  .016) vs placebo. Overall, the relative risk for any adverse event with atogepant vs placebo treatment was 1.07 (P  =  .630).

Study details: The data come from a systematic review and meta-analysis of 2 randomized controlled trials including 1550 patients with episodic migraine who were randomly assigned to receive 10 mg atopegant (n = 314), 30 mg atogepant (n = 411), 60 mg atopegant (n = 417), or placebo (n = 408).

Disclosures: This study did not receive any funding. Some authors declared receiving grants or serving as speakers, consultants, or on advisory boards for various sources.

Source: Lattanzi S et al. Atogepant for the prevention of episodic migraine in adults: A systematic review and meta-analysis of efficacy and safety. Neurol Ther. 2022 (Jun 15). Doi:  10.1007/s40120-022-00370-8

Key clinical point: Once-daily oral atogepant was overall safe and effective for the prevention of episodic migraine in adults.

Major finding: The reduction in the mean number of migraine days across the 12-week treatment period was significantly greater with 10 mg atogepant (mean difference [MD] −1.16; P < .001), 30 mg (MD −1.15; P < .001), or 60 mg (MD −1.20; P  =  .016) vs placebo. Overall, the relative risk for any adverse event with atogepant vs placebo treatment was 1.07 (P  =  .630).

Study details: The data come from a systematic review and meta-analysis of 2 randomized controlled trials including 1550 patients with episodic migraine who were randomly assigned to receive 10 mg atopegant (n = 314), 30 mg atogepant (n = 411), 60 mg atopegant (n = 417), or placebo (n = 408).

Disclosures: This study did not receive any funding. Some authors declared receiving grants or serving as speakers, consultants, or on advisory boards for various sources.

Source: Lattanzi S et al. Atogepant for the prevention of episodic migraine in adults: A systematic review and meta-analysis of efficacy and safety. Neurol Ther. 2022 (Jun 15). Doi:  10.1007/s40120-022-00370-8

Key clinical point: Once-daily oral atogepant was overall safe and effective for the prevention of episodic migraine in adults.

Major finding: The reduction in the mean number of migraine days across the 12-week treatment period was significantly greater with 10 mg atogepant (mean difference [MD] −1.16; P < .001), 30 mg (MD −1.15; P < .001), or 60 mg (MD −1.20; P  =  .016) vs placebo. Overall, the relative risk for any adverse event with atogepant vs placebo treatment was 1.07 (P  =  .630).

Study details: The data come from a systematic review and meta-analysis of 2 randomized controlled trials including 1550 patients with episodic migraine who were randomly assigned to receive 10 mg atopegant (n = 314), 30 mg atogepant (n = 411), 60 mg atopegant (n = 417), or placebo (n = 408).

Disclosures: This study did not receive any funding. Some authors declared receiving grants or serving as speakers, consultants, or on advisory boards for various sources.

Source: Lattanzi S et al. Atogepant for the prevention of episodic migraine in adults: A systematic review and meta-analysis of efficacy and safety. Neurol Ther. 2022 (Jun 15). Doi:  10.1007/s40120-022-00370-8

Key clinical point: Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) could serve as effective diagnostic biomarkers for pediatric migraine.

Major finding: The plasma levels of CGRP and PACAP-38 were significantly higher in patients with migraine in the ictal and interictal periods and with and without aura compared with healthy controls (P < .001), with PACAP-38 (adjusted odds ratio [aOR] 1.331; P < .001) and CGRP (aOR 1.113; P < .001) being independent risk factors for the diagnosis of pediatric migraine.

Study details: This was a prospective study of 76 patients aged 4-18 years with migraine and 77 age-matched healthy controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu J et al. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain. 2022;23:68 (Jun 13). Doi: 10.1186/s10194-022-01435-7

Key clinical point: Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) could serve as effective diagnostic biomarkers for pediatric migraine.

Major finding: The plasma levels of CGRP and PACAP-38 were significantly higher in patients with migraine in the ictal and interictal periods and with and without aura compared with healthy controls (P < .001), with PACAP-38 (adjusted odds ratio [aOR] 1.331; P < .001) and CGRP (aOR 1.113; P < .001) being independent risk factors for the diagnosis of pediatric migraine.

Study details: This was a prospective study of 76 patients aged 4-18 years with migraine and 77 age-matched healthy controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu J et al. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain. 2022;23:68 (Jun 13). Doi: 10.1186/s10194-022-01435-7

Key clinical point: Calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) could serve as effective diagnostic biomarkers for pediatric migraine.

Major finding: The plasma levels of CGRP and PACAP-38 were significantly higher in patients with migraine in the ictal and interictal periods and with and without aura compared with healthy controls (P < .001), with PACAP-38 (adjusted odds ratio [aOR] 1.331; P < .001) and CGRP (aOR 1.113; P < .001) being independent risk factors for the diagnosis of pediatric migraine.

Study details: This was a prospective study of 76 patients aged 4-18 years with migraine and 77 age-matched healthy controls.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Liu J et al. CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain. 2022;23:68 (Jun 13). Doi: 10.1186/s10194-022-01435-7

Key clinical point: Migraine was significantly associated with the incidence of ocular motor cranial nerve palsy (OMCNP), with the risk being particularly high among patients with migraine who smoked or had diabetes mellitus.

Major finding: The incidence of OMCNP was significantly higher in patients with vs without migraine (adjusted hazard ratio [aHR] 1.166; 95% CI 1.013-1.343), with the association being strongest among those who smoked (aHR 1.426; 95% CI 1.127-1.803) and had diabetes mellitus (aHR 1.378; 95% CI 1.045-1.378).

Study details: This was a population-based, observational, retrospective cohort study including 4,053,824 medical beneficiaries; of which 5806 developed OMCNP and 4,048,018 did not develop OMCNP (control population). A subgroup of 111,853 patients had migraine.

Disclosures: This study was supported by a National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Rhiu S et al. Association between migraine and risk of ocular motor cranial nerve palsy. Sci Rep. 2022;12:10512 (Jun 22). Doi: 10.1038/s41598-022-14621-z

Key clinical point: Migraine was significantly associated with the incidence of ocular motor cranial nerve palsy (OMCNP), with the risk being particularly high among patients with migraine who smoked or had diabetes mellitus.

Major finding: The incidence of OMCNP was significantly higher in patients with vs without migraine (adjusted hazard ratio [aHR] 1.166; 95% CI 1.013-1.343), with the association being strongest among those who smoked (aHR 1.426; 95% CI 1.127-1.803) and had diabetes mellitus (aHR 1.378; 95% CI 1.045-1.378).

Study details: This was a population-based, observational, retrospective cohort study including 4,053,824 medical beneficiaries; of which 5806 developed OMCNP and 4,048,018 did not develop OMCNP (control population). A subgroup of 111,853 patients had migraine.

Disclosures: This study was supported by a National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Rhiu S et al. Association between migraine and risk of ocular motor cranial nerve palsy. Sci Rep. 2022;12:10512 (Jun 22). Doi: 10.1038/s41598-022-14621-z

Key clinical point: Migraine was significantly associated with the incidence of ocular motor cranial nerve palsy (OMCNP), with the risk being particularly high among patients with migraine who smoked or had diabetes mellitus.

Major finding: The incidence of OMCNP was significantly higher in patients with vs without migraine (adjusted hazard ratio [aHR] 1.166; 95% CI 1.013-1.343), with the association being strongest among those who smoked (aHR 1.426; 95% CI 1.127-1.803) and had diabetes mellitus (aHR 1.378; 95% CI 1.045-1.378).

Study details: This was a population-based, observational, retrospective cohort study including 4,053,824 medical beneficiaries; of which 5806 developed OMCNP and 4,048,018 did not develop OMCNP (control population). A subgroup of 111,853 patients had migraine.

Disclosures: This study was supported by a National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Rhiu S et al. Association between migraine and risk of ocular motor cranial nerve palsy. Sci Rep. 2022;12:10512 (Jun 22). Doi: 10.1038/s41598-022-14621-z

Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206